The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Implementation of clinical next-generation sequencing (NGS) of non-small cell lung cancer (NSCLC) to identify EGFR amplification as a potentially targetable oncogenic alteration.
Geoffrey R. Oxnard
Consultant or Advisory Role - Astellas Pharma (U); AstraZeneca; AVEO; Boehringer Ingelheim; Genentech; Novartis
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma
Christine A. Lydon
No relevant relationships to disclose
Neal Ian Lindeman
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca
Priyanka R. Shivdasani
No relevant relationships to disclose
Gary Y. Chin
No relevant relationships to disclose
Frank C. Kuo
No relevant relationships to disclose
Bruce E. Johnson
Consultant or Advisory Role - Acceleron Pharma; AstraZeneca; Chugai Pharma; Genentech; KEW Group; Millennium; Pfizer; Teva; Transgenomic; Veridex
Other Remuneration - Genzyme
Pasi A. Janne
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Clovis; Genentech; Merrimack Pharmaceuticals ; Pfizer; Sanofi
Stock Ownership - GATEKEEPER Pharmaceuticals
Other Remuneration - LabCorp
Lynette M. Sholl
No relevant relationships to disclose